^
    1year
    ON-5001: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (clinicaltrials.gov)
    P1, N=168, Recruiting, OncoNano Medicine, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Libtayo (cemiplimab-rwlc) • ONM-501
    1year
    ON-5001: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. (clinicaltrials.gov)
    P1, N=168, Not yet recruiting, OncoNano Medicine, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Libtayo (cemiplimab-rwlc) • ONM-501
    over2years
    ONM-501: A polyvalent STING agonist for oncology immunotherapy (AACR 2022)
    ONM-501 demonstrated marked anti-tumor efficacy in a panel of syngeneic tumor models. The anti-tumor effect was mediated by host STING and dependent on CD8+ T cells and DCs. These results support further evaluation of ONM-501 as a clinical candidate for the potential treatment of solid tumors.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • STING (stimulator of interferon response cGAMP interactor 1) • IFNB1 (Interferon Beta 1)
    |
    ONM-501